Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560
Debt
Debt-to-Equity Ratio1.00
Current Ratio8.66
Quick Ratio7.83
Price-To-Earnings
Trailing P/E Ratio-63.97
Forward P/E Ratio-67.73
P/E GrowthN/A
Sales & Book Value
Annual Sales$286.63 million
Price / Sales5.29
Cash Flow$0.0618 per share
Price / Cash603.18
Book Value$6.89 per share
Price / Book5.41
Profitability
EPS (Most Recent Fiscal Year)($0.58)
Net Income$-42,610,000.00
Net Margins-11.45%
Return on Equity-5.81%
Return on Assets-2.56%
Miscellaneous
Employees489
Outstanding Shares40,730,000
Market Cap$1,509.13
Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions
What is Pacira Pharmaceuticals' stock symbol?
Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."
How were Pacira Pharmaceuticals' earnings last quarter?
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced its earnings results on Thursday, May, 3rd. The company reported $0.02 earnings per share for the quarter, hitting analysts' consensus estimates of $0.02. The business earned $74.61 million during the quarter, compared to the consensus estimate of $73.92 million. Pacira Pharmaceuticals had a negative net margin of 11.45% and a negative return on equity of 5.81%. Pacira Pharmaceuticals's quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.19) earnings per share. View Pacira Pharmaceuticals' Earnings History.
When is Pacira Pharmaceuticals' next earnings date?
What price target have analysts set for PCRX?
21 brokers have issued 12 month price objectives for Pacira Pharmaceuticals' shares. Their predictions range from $27.00 to $80.00. On average, they expect Pacira Pharmaceuticals' stock price to reach $45.1765 in the next twelve months. This suggests a possible upside of 21.3% from the stock's current price. View Analyst Ratings for Pacira Pharmaceuticals.
What is the consensus analysts' recommendation for Pacira Pharmaceuticals?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Pharmaceuticals in the last year. There are currently 1 sell rating, 11 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about Pacira Pharmaceuticals stock?
Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Pacira’s top line mainly comprises contribution from its marketed product-Exparel. It is making efforts to expand Exparel's label. In April 2018, the FDA approved Pacira’s sNDA seeking expansion of the Exparel label to include administration via nerve block for prolonged regional analgesia. However, the company is heavily dependent on Exparel for growth, which accounts for a significant chunk of its revenues. This is a concern for the company. Exparel also competes with well-established products for postsurgical pain management." (7/15/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks. Our $48 12-month target is based on an average of our $55/share DCF (10% WACC discount rate; 1% terminal growth beyond 2024) and a $41/share P/E multiple derived valuation (30x fully-taxed 2020 EPS, or 1x PEG, discounted back)." (7/10/2018)
- 3. Mizuho analysts commented, "We switched from Symphony Health data last month, after a sizeable data restatement from the vendor rendered our prior estimates unreliable." (6/29/2018)
- 4. Canaccord Genuity analysts commented, "We’re looking for more than two months of data showing solid growth before we become positive on the potential for a meaningful inflection in Exparel use trends, especially with a noisy October that may have benefited from hurricane-related deferred procedures that negatively impacted September volumes. We remain HOLD rated on PCRX shares." (12/29/2017)
Who are some of Pacira Pharmaceuticals' key competitors?
Some companies that are related to Pacira Pharmaceuticals include Catalent (CTLT), Ionis Pharmaceuticals (IONS), FibroGen (FGEN), Loxo Oncology (LOXO), United Therapeutics (UTHR), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Madrigal Pharmaceuticals (MDGL) and Array Biopharma (ARRY).
Who are Pacira Pharmaceuticals' key executives?
Pacira Pharmaceuticals' management team includes the folowing people:
- Mr. David M. Stack, Chairman and Chief Exec. Officer (Age 68)
- Mr. Charles A. Reinhart III, Chief Financial Officer (Age 57)
- Ms. Kristen Williams J.D., Chief Admin. Officer, Gen. Counsel and Sec. (Age 44)
- Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 39)
- Dr. Richard Scranton M.D., MPH, Chief Scientific Officer
Has Pacira Pharmaceuticals been receiving favorable news coverage?
News coverage about PCRX stock has been trending somewhat positive this week, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pacira Pharmaceuticals earned a media sentiment score of 0.08 on Accern's scale. They also assigned news articles about the company an impact score of 46.52 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Pacira Pharmaceuticals' major shareholders?
Pacira Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (1.43%), Peregrine Capital Management LLC (0.66%), Bank of Montreal Can (0.09%), Pendal Group Ltd (0.06%), Xact Kapitalforvaltning AB (0.02%) and Benjamin F. Edwards & Company Inc. (0.01%). Company insiders that own Pacira Pharmaceuticals stock include Charles A Reinhart III, David M Stack, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings, Richard Scranton and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.
Which major investors are selling Pacira Pharmaceuticals stock?
PCRX stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Bank of Montreal Can and Benjamin F. Edwards & Company Inc.. Company insiders that have sold Pacira Pharmaceuticals company stock in the last year include Charles A Reinhart III, David M Stack, James B Jones, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Pharmaceuticals.
Which major investors are buying Pacira Pharmaceuticals stock?
PCRX stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Xact Kapitalforvaltning AB and Pendal Group Ltd. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include Mark A Kronenfeld and Mark Froimson. View Insider Buying and Selling for Pacira Pharmaceuticals.
How do I buy shares of Pacira Pharmaceuticals?
Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pacira Pharmaceuticals' stock price today?
One share of PCRX stock can currently be purchased for approximately $37.25.
How big of a company is Pacira Pharmaceuticals?
Pacira Pharmaceuticals has a market capitalization of $1.51 billion and generates $286.63 million in revenue each year. The company earns $-42,610,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Pacira Pharmaceuticals employs 489 workers across the globe.
How can I contact Pacira Pharmaceuticals?
Pacira Pharmaceuticals' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]
MarketBeat Community Rating for Pacira Pharmaceuticals (NASDAQ PCRX)
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
